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Abstract
Rationale:Mechanisms contributing to chronic lung disease after
preterm birth are incompletely understood.
Objectives: To identify antenatal risk factors associated with
increased risk for bronchopulmonary dysplasia (BPD) and
respiratory disease during early childhood after preterm birth,
we performed a prospective, longitudinal study of 587 preterm
infants with gestational age less than 34 weeks and birth weights
between 500 and 1,250 g.
Methods: Data collected included perinatal information and
assessments during the neonatal intensive care unit admission and
longitudinal follow-up by questionnaire until 2 years of age.
Measurements and Main Results: After adjusting for covariates,
we found that maternal smoking prior to preterm birth increased the
odds of having an infant with BPD by twofold (P = 0.02). Maternal
smoking was associated with prolonged mechanical ventilation and
respiratory support during the neonatal intensive care unit
admission. Preexisting hypertension was associated with a twofold
(P = 0.04) increase in odds for BPD. Lower gestational age and
birth weight z-scores were associated with BPD. Preterm infants who
were exposed tomaternal smoking hadhigher rates of late respiratory
disease during childhood. Twenty-two percent of infants diagnosed
with BPD and 34% of preterm infants without BPD had no clinical
signs of late respiratory disease during early childhood.
Conclusions:We conclude that maternal smoking and
hypertension increase the odds for developing BPD after preterm
birth, and that maternal smoking is strongly associated with
increased odds for late respiratory morbidities during early
childhood. These findings suggest that in addition to the BPD
diagnosis at 36 weeks, other factors modulate late respiratory
outcomes during childhood. We speculate that measures to reduce
maternal smoking not only will lower the risk for preterm birth
but also will improve late respiratory morbidities after preterm birth.
Keywords: prematurity; maternal smoking; bronchopulmonary
dysplasia; hypertensive disorders of pregnancy; preeclampsia
Despite improvements in perinatal care,
preterm children remain at high risk for
mortality and significant respiratory
morbidities owing to the development of
bronchopulmonary dysplasia (BPD) (1).
BPD is the chronic lung disease of
prematurity that develops in infants who
require respiratory support at birth owing
to immaturity of the preterm lung (2). BPD
occurs in roughly 45% of infants born at
less than or equal to 29 weeks of gestation
with birth weights between 400 and 1,500 g,
with approximately 10,000–15,000 new
cases reported each year (1, 3, 4). The
incidence of BPD has not changed over the
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past few decades, reflecting improved
survival of extremely preterm infants who
are at highest risk for BPD (5).
BPD is also associated with significant
neonatal intensive care unit (NICU)-related
complications, including the prolonged
need for mechanical ventilation, respiratory
support, and oxygen therapy; longer
duration of hospitalization; and higher rates
of nonrespiratory comorbidities, such as
retinopathy of prematurity and brain injury
(5, 6). After NICU discharge, infants with
BPD often require frequent hospital
readmissions and have high rates of
emergency room or physician visits for
recurrent respiratory exacerbations,
infections, and reactive airway disease.
Sustained abnormalities of lung function,
poor exercise tolerance, and the need for
chronic respiratory medications throughout
childhood and adolescence are also
increased in former preterm infants (7, 8).
Past studies have shown that over 50% of
preterm infants subsequently require
rehospitalizations or chronic respiratory
medications after NICU discharge,
including preterm infants without a formal
diagnosis of BPD (8). Controversies persist
regarding how best to define BPD and
whether bearing this diagnosis at 36 weeks
postmenstrual age (PMA) adequately
reflects the late risk for lung disease during
childhood and into adult life (9–11).
Although postnatal factors, such as
hyperoxia, mechanical ventilation,
prolonged patency of the ductus arteriosus,
sepsis, inflammation, and others, increase
the risk for BPD, epidemiologic studies have
further identified important roles for
antenatal factors as well (12–19). Adverse
antenatal factors, such as chorioamnionitis,
preeclampsia, preexisting hypertensive
disorders, obesity, and others, have been
variably associated with an increased risk
for BPD (11, 15–22). Maternal smoking has
also been linked with an increased rate of
preterm birth (23, 24). In addition, past
studies further suggest that maternal
smoking is associated with a higher risk for
lung disease in children (25–27).
Recently, participants in an NHLBI-
sponsored workshop discussed the
importance of prenatal and early postnatal
influences on lung growth and development
on subsequent respiratory function and
disease throughout childhood (11). This
workshop further highlighted major gaps in
understanding of how environmental and
maternal factors can impact late respiratory
outcomes during early childhood, and that
the exact relationships between prenatal
exposures and early postnatal events on the
subsequent development of late respiratory
disease during infancy, especially after
preterm birth, remain uncertain. Because
an increasing number of studies have
shown that preterm birth alone is
associated with late respiratory disease in
childhood, links between the diagnosis of
BPD at 36 weeks corrected age and
persistent chronic lung disease during
infancy and beyond remain unclear.
To better understand antenatal risk factors
associated with the development of BPD and
late respiratory disease during early childhood
after premature birth, and to examine the
relationship between the diagnosis of BPD and
respiratory disease after NICU discharge, we
completed a prospective longitudinal study of
a cohort of preterm infants. We collected
extensive perinatal data and performed serial
assessments during NICU admission and
longitudinal follow-up by questionnaire to
evaluate the potential contributions of antenatal
factors that increase the risk for BPD, modulate
the clinical severity of BPD, and contribute to
persistent respiratory disease throughout early
infancy. We further examined the relationship
between the current diagnosis of BPD at
36 weeks PMA and subsequent respiratory
morbidities during early childhood.
Methods
Study Population
All data were obtained between July 2006 and
November 2016 as part of a prospective
observational research protocol that was
reviewed and approved by the institutional
review boards of the respective sites. Written
informed consent was received from the parents
or guardians of all participants. The study
population consisted of subjects enrolled in a
prospective study of premature infants at risk for
BPD (NHLBI grant HL085703). Participants
were preterm infants fromfive centerswhohad a
gestational age less than or equal to 34 weeks,
birth within the previous 7 days, and a birth
weight between 500 and 1,250 g.
Study Design
Data were prospectively collected and
managed using a REDCap database hosted
at the University of Colorado Denver (28).
BPD status and severity were assessed at
36 weeks PMA using a modification of the
National Institutes of Health workshop
definition (3) with application of the
oxygen reduction test (29). For some
analyses, comparisons were made regarding
the presence or absence of BPD, which
was defined as children having either no or
mild BPD versus those diagnosed with
moderate or severe BPD. Birth weight
z-scores were calculated by the methods of
Oken and colleagues (30). Maternal
smokers were self-identified at the initial
patient assessment. A newborn was
considered as small for gestational age if the
birth weight z-score was below the 10th
percentile for sex and gestational age. For
subjects with a small number of missing
variables (three or fewer), their medical
records were assumed to be complete, and
the missing values were imputed, except for
the following variables, which were not
changed: corticosteroids, pregestational
diabetes, antibiotic use, maternal fever, or
tocolytic medications. Variables with missing
values for all other records were left as
unknown. The number of events restricted
our number of predictors in the model to 20,
which were selected on the basis of a priori
clinical knowledge. We excluded four subjects
At a Glance Commentary
Scientific Knowledge on the
Subject: Despite improvements in
perinatal care, preterm infants
remain at high risk for developing
bronchopulmonary dysplasia (BPD) and
late respiratory disease during childhood.
Antenatal factors that contribute to the
development of BPD and late respiratory
problems during infancy are incompletely
understood. In addition, the relationship
between risk for BPD and late respiratory
sequelae are uncertain.
What This Study Adds to the
Field: Data derived from this
prospective, longitudinal multicenter
study show that maternal smoking and
preexisting hypertension increase the
odds for developing BPD after preterm
birth and that maternal smoking is
strongly associated with increased odds
for late respiratory morbidities during
early childhood. These findings suggest
that in addition to BPD diagnosis at
36 weeks corrected age, other factors
modulate late respiratory outcomes
during childhood.
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with three or more missing variables from the
analysis rather than attempting to impute a
large proportion of missing information for a
given subject. Follow-up surveys were
administered at 6-month intervals to examine
respiratory health over the first 2 years of
life, which included questions regarding
environmental exposures to secondhand
smoke and to pets. A child was considered
to have a diagnosis of late respiratory
disease if any of the following events
occurred over the first 2 years of life: one
or more respiratory hospitalizations; use of
inhaled steroids, inhaled bronchodilators,
and/or diuretics; and a physician’s
diagnosis of asthma, reactive airway
disease, or a BPD exacerbation.
Statistical Analysis
Chi-square tests, Fisher’s exact tests, and
Wilcoxon signed-rank tests were used to
assess associations across BPD and late
respiratory outcome status for categorical
and continuous variables, respectively. A
logistic regression model was fitted using an
outcome of moderate or severe BPD at
36 weeks PMA. Perinatal risk factors and
potential confounders were identified
a priori on the basis of clinical importance
and were restricted to an appropriate
number based on the number of events
(see Table 1) (31). To facilitate clinical
interpretation, signs were reversed for
birth weight z-score, maternal age, and
gestational age. A similar logistic regression
was fitted modeling the diagnosis of late
respiratory disease using a reduced set of
the covariates from the prior model.
Interactions of maternal smoking with all
other covariates were tested. Two logistic
regressions were fitted on the diagnosis of
late respiratory disease using dichotomized
BPD and the classification of BPD severity
as the only predictors. All analyses were
performed using SAS version 9.4 software
(SAS Institute, Cary, NC).
Results
Characteristics of the 587 infants enrolled
across sites are stratified by BPD status
(Table 1). The median birth weight and
gestational age were 930 g and 27 weeks,
respectively. Most of the mothers in this
study were non-Hispanic (79%) and white
(77%). Smoking was reported by 14% of
mothers (Table 2). The diagnosis of BPD
disease severity included mild (n = 214
[36.5%]), moderate (n = 119 [20.3%]), and
severe (n = 123 [21.0%]) categories.
Applying a dichotomized diagnosis of BPD
status, 242 (41.2%) infants developed
moderate or severe BPD, and 345 (58.8%)
infants did not develop BPD (n = 131
[22.3%]) or developed only mild disease
Table 1. Subject Characteristics by Bronchopulmonary Dysplasia Status
All Subjects (n = 587) No or Mild BPD (n = 345) Moderate or Severe BPD (n = 242) P Value*
Birth weight, g 930 (758 to 1,080) 1,000 (855 to 1,125) 800 (680 to 970) ,0.01
Birth weight z-score 20.24 (20.82 to 0.29) 20.24 (20.94 to 0.29) 20.25 (20.69 to 0.29) 0.20
Birth weight strata, g
500–749 (n = 136) 136 (23%) 46 (13.3%) 90 (37.2%) ,0.01
750–999 (n = 220) 223 (37.7%) 123 (35.7%) 100 (41.3%) 0.16
1,000–1,250 (n = 219) 228 (38.6%) 176 (51%) 52 (21.5%) ,0.01
Small for gestational age 158 (26.7%) 92 (26.7%) 66 (27.3%) 0.87
Birth length, cm 35 (32.5 to 37) 35.5 (34 to 37.2) 33 (31.5 to 35.6) ,0.01
Head circumference, cm 24.5 (23 to 26) 25.05 (24 to 26.5) 23.5 (22 to 25) ,0.01
Gestational age, wk 27 (26 to 28) 27 (26 to 29) 26 (24 to 27) ,0.01
Maternal age, yr 28 (23 to 32) 28 (23 to 33) 28 (23 to 31) 0.14
Male sex 299 (50.6%) 164 (47.5%) 135 (55.8%) 0.05
Maternal race
Asian 7 (1.2%) 4 (1.2%) 3 (1.2%) 0.93
Black or African American 119 (20.1%) 77 (22.3%) 42 (17.4%) 0.14
Hawaiian or Pacific Islander 0 (0%) 0 (0%) 0 (0%) —
White 457 (77.3%) 262 (75.9%) 195 (80.6%) 0.18
Other 1 (0.2%) 0 (0%) 1 (0.4%) —
Unknown 3 (0.5%) 3 (0.9%) 0 (0%) 0.15
Maternal ethnicity
Hispanic or Latino 119 (20.1%) 73 (21.2%) 46 (19.0%) 0.52
Not Hispanic or Latino 467 (79.0%) 271 (78.6%) 196 (81.0%) 0.47
Multiple gestations 143 (24.2%) 87 (25.2%) 56 (23.1%) 0.56
Antenatal corticosteroids 487 (82.4%) 289 (83.8%) 198 (81.8%) 0.42
Cesarean section delivery 408 (69.0%) 250 (72.5%) 158 (65.3%) 0.06
Intubated in delivery room 363 (61.4%) 180 (52.2%) 183 (75.6%) 0.02
Intubated in NICU 122 (20.6%) 74 (21.4%) 48 (19.8%) 0.11
Surfactant in delivery room 460 (77.8%) 239 (69.3%) 221 (91.3%) ,0.01
PDA medical treatment 245 (41.5%) 120 (34.8%) 125 (51.7%) ,0.05
PDA surgical ligation 74 (12.5%) 21 (6.1%) 53 (21.9%) ,0.01
IVH grade 3 or 4 24 (4.1%) 8 (2.3%) 16 (6.6%) 0.01
Threshold ROP 47 (8.0%) 8 (2.3%) 39 (16.1%) ,0.01
Definition of abbreviations: BPD = bronchopulmonary dysplasia; IVH = intraventricular hemorrhage; NICU = neonatal intensive care unit; PDA = patent
ductus arteriosus; ROP = retinopathy of prematurity.
Descriptive statistics [count (percent) or median (interquartile range)] are displayed for the demographics of the study population, stratified by
bronchopulmonary dysplasia severity. Univariate comparisons were made across bronchopulmonary dysplasia severity outcomes.
*P value denotes comparison of last two columns.
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(n = 214 [36.5%]). More infants with
moderate and severe BPD had severe
intraventricular hemorrhage (P = 0.01) and
more often were treated with surgical ligation
of a patent ductus arteriosus (P, 0.01) than
those with no or mild BPD (Table 1).
A univariate analysis between antenatal
events and dichotomized BPD status yielded a
significant relationship between maternal
smoking and the development of BPD after
preterm birth (P, 0.01) (Table 2). Of those
children who developed moderate or severe
BPD, 18.6% had mothers who smoked
during pregnancy. Of those who developed
mild or no BPD, 10.1% had mothers who
smoked during pregnancy. None of the other
antenatal events were significantly associated
with BPD.
A multiple linear logistic regression
was fitted to the diagnosis of BPD (Table 3)
(c-index, 0.77). There was a significant
association between maternal smoking and
BPD severity. After adjusting for covariates,
we found that mothers who smoked while
pregnant increased their odds of having an
infant with moderate or severe BPD by
2.02-fold (95% confidence interval (CI),
1.09–3.74; P = 0.02). Preexisting maternal
hypertension was associated with a 2.11
times increase in the odds of BPD severity
(95% CI, 1.05–4.24; P = 0.04). Children of
white mothers had a 1.85-times increase in
the odds of BPD severity at 36 weeks than
those of other races (95% CI, 1.11–3.08;
P = 0.02). As expected, lower gestational age
(weeks) (odds ratio [OR], 1.89; 95% CI,
1.65–2.17; P, 0.01) and lower birth weight
z-scores (OR, 2.40; 95% CI, 1.66–3.46;
P, 0.01) were also significantly associated
with an increase in BPD severity. Cesarean
section delivery was associated with a lower
odds (OR, 0.63; 95% CI, 0.40–0.99; P =
0.05). The ORs from the model are ranked
graphically in Figure 1. Interactions of
maternal smoking with all other covariates
Table 2. Maternal Complications by Bronchopulmonary Dysplasia Status
All Subjects (n = 587) No or Mild BPD (n = 345) Moderate or Severe BPD (n = 242) P Value*
Preexisting diabetes 22 (3.7%) 15 (4.3%) 7 (2.9%) 0.33
Gestational diabetes 40 (6.8%) 27 (7.8%) 13 (5.4%) 0.24
Preexisting hypertension 67 (11.3%) 37 (10.7%) 30 (12.4%) 0.55
Prolonged rupture of membranes 107 (18.1%) 64 (18.6%) 43 (17.8%) 0.86
Chorioamnionitis 110 (18.6%) 61 (17.7%) 49 (20.2%) 0.38
Preeclampsia 154 (26.1%) 98 (28.4%) 56 (23.1%) 0.17
Antepartum hemorrhage 67 (11.3%) 33 (9.6%) 34 (14.0%) 0.09
Maternal smoking 80 (13.5%) 35 (10.1%) 45 (18.6%) ,0.01
Maternal alcohol use 13 (2.2%) 6 (1.7%) 7 (2.9%) 0.35
Maternal substance abuse 50 (8.5%) 27 (7.8%) 23 (9.5%) 0.47
Definition of abbreviation: BPD = bronchopulmonary dysplasia.
Descriptive statistics [count (percent)] are presented for maternal complications calculated for the entire study population, stratified by bronchopulmonary
dysplasia severity. Univariate comparisons were made across bronchopulmonary dysplasia severity outcomes.
*P value denotes comparison of last two columns.
Table 3. Model Results of Logistic Regression for Bronchopulmonary Dysplasia Status
Parameter Odds Ratio 95% Confidence Interval P Value
Decreasing birth weight z-score, 1 SD 2.40 1.66–3.46 ,0.01
Male sex 1.37 0.92–2.03 0.12
Maternal race: white 1.85 1.11–3.08 0.02
Maternal ethnicity: Hispanic or Latino 0.70 0.42–1.17 0.17
Decreasing gestational age, wk 1.89 1.65–2.17 ,0.01
Maternal smoking status 2.02 1.09–3.74 0.02
Antenatal corticosteroids 0.90 0.51–1.59 0.71
Multiple gestations 1.50 0.92–2.44 0.10
Cesarean section delivery 0.63 0.40–0.99 0.05
Preexisting diabetes 0.92 0.32–2.65 0.87
Gestational diabetes 1.23 0.56–2.67 0.61
Preexisting hypertension 2.11 1.05–4.24 0.04
Prolonged rupture of membranes 0.86 0.50–1.48 0.59
Chorioamnionitis 0.87 0.51–1.48 0.60
Preeclampsia 0.97 0.55–1.70 0.92
Antepartum hemorrhage 1.13 0.62–2.05 0.69
Decreasing maternal age, yr 1.01 0.98–1.05 0.57
Maternal alcohol consumption 0.97 0.20–4.70 0.97
Maternal drug use 0.94 0.44–2.02 0.88
Tocolytics 1.08 0.72–1.63 0.71
Risk factors for bronchopulmonary dysplasia: parametric estimates, Wald 95% confidence intervals, and P values derived from the logistic regression
analysis modeling bronchopulmonary dysplasia severity.
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were tested, and none yielded significant
associations with smoking status, including
degree of prematurity.
To further investigate the impact of
maternal smoking, univariate analyses
between postnatal NICU events and
maternal smoking status were performed
(Table 4). The requirement for continuous
positive airway pressure at 36 weeks PMA
was marginally greater in infants from
maternal smokers and nonsmokers
(P = 0.06). For mothers who smoked during
pregnancy, 11.3% of their children required
continuous positive airway pressure at
36 weeks PMA, whereas only 5.7% of
children whose mothers did not smoke
required the treatment. The median number
of days on mechanical ventilation for a child
of a maternal smoker was greater than that
for infants born from nonsmoker mothers
(14 vs. 6 d; P = 0.04). As a sensitivity analysis,
we evaluated whether the association with
smoking remained between the four-
category BPD variable (none, mild,
moderate, and severe). The risk was similar
between the groups that were combined
(see online supplement). When we used
an ordinal model for multinomial data
(four-category BPD), maternal smoking
remained significant after adjusting for the
other covariates (OR, 1.7; 95% CI,
1.03–2.81; P = 0.04). We evaluated many
potential interactions with the smoking
variable, but none of the interactions
reached statistical significance (see online
supplement). Variables were selected for
inclusion in the model on the basis of
a priori knowledge of clinical importance.
Follow-up surveys were used to
examine risk factors for continuing
respiratory problems. Five hundred thirty-
seven of the 587 children (91.5%) completed
one or more surveys. Of these, 223
completed all four, 134 completed three,
110 completed two, and 70 completed only
one. Of 537 children with at least one survey,
372 infants (69.3%) had late respiratory
disease during early childhood, as defined
above. There were 13 children (2.4%) whose
respiratory diagnosis could not be
computed, owing to missing questions.
Similar BPD rates (44% vs. 41%), maternal
ages (mean, 27.2 vs. 27.8 yr), and gestational
ages (mean, 26.6 vs. 27.0 wk) were observed
for the subjects who had a missing
respiratory diagnosis. More of the subjects
with missing respiratory diagnoses than
those with respiratory diagnosis
information were smokers (22% vs. 13%;
P = 0.04). By univariate analysis, there were
significant differences in gestational age
(P, 0.01) and maternal age (P = 0.01)
between those who had a late respiratory
OR and 95% CI
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Negative Maternal Age (Years)
Maternal Race: White
Maternal Ethnicity: Hispanic or Latino
Cesarean
Antepartum Hemorrhage
Tocolytics
Gestational Diabetes
Antenatal Corticosteroids
Chorioamnionitis
Maternal Drug Usage
Prolonged Rupture of Membranes
Pre-existing Diabetes
Pre-existing Hypertension
Multiple Gestations
Gender: Male
Pre-eclampsia
Maternal Alcohol Consumption
Maternal Smoking Status
Negative Gestational Age (Weeks)
Negative Birthweight Z-Score
543210 6
Figure 1. Odds ratios (ORs) with 95% confidence intervals (CIs) for model covariates from the logistic
regression analysis modeling bronchopulmonary dysplasia severity.
Table 4. Postnatal Neonatal Intensive Care Unit Events by Maternal Smoking Status
Postnatal NICU Events (n = 587) Smokers (n = 80) Nonsmokers (n = 507) P Value
Pneumonia 10 (12.5%) 48 (9.5%) 0.40
Necrotizing enterocolitis 10 (12.5%) 56 (11.0%) 0.70
Sepsis 16 (20%) 93 (18.3%) 0.72
Threshold retinopathy 9 (11.3%) 38 (7.5%) 0.25
Days of CPAP 12.5 (4.5–23) 14 (6–29) 0.13
Required CPAP at 36 wk PMA 9 (11.3%) 29 (5.7%) 0.06
Days of MV 14 (2–40) 6 (2–21) 0.04
Required MV at 36 wk PMA 7 (8.8%) 23 (4.5%) 0.44
Length of stay in NICU 91.5 (74–118) 85 (70–110) 0.11
Discharged on oxygen 48 (60.0%) 293 (57.8%) 0.71
Mortality 2 (2.5%) 6 (1.2%) 0.35
Total oxygen days (includes 1-yr follow-up) 73 (39.5–110.5) 73 (43.5–98) 0.68
Definition of abbreviations: CPAP = continuous positive airway pressure; MV =mechanical ventilation; NICU = neonatal intensive care unit;
PMA = postmenstrual age.
Descriptive statistics [count (percent) or median (interquartile range)] and univariate comparisons are presented for postnatal neonatal intensive care unit
events, stratified by maternal smoking status.
ORIGINAL ARTICLE
368 American Journal of Respiratory and Critical Care Medicine Volume 196 Number 3 | August 1 2017
diagnosis and those who did not (Table 5).
There was a higher percentage of children
with a late respiratory diagnosis who were
from black or African American parents
(P, 0.01) than those without a diagnosis.
There was a lower percentage of white
children who were diagnosed with a late
respiratory diagnosis than those who were
not (P, 0.01). Children of mothers who
smoked during pregnancy were more likely
to develop a respiratory disorder (P = 0.02)
(Table 6). Pregnancies complicated by
chorioamnionitis had a higher rate of
children with a late respiratory diagnosis
than those that did not (P = 0.03). Children
who were given a surfactant in the delivery
room were more likely to develop a
respiratory disorder (P, 0.01), and
those with threshold retinopathy of
prematurity had a higher diagnosis rate
(P = 0.01).
Of the children diagnosed with a
respiratory disease in the first 2 years of life,
45% had moderate or severe BPD (Table 5).
Similarly, of the children who were not
diagnosed with a respiratory disease, 69%
had no or mild BPD. A logistic regression
was fitted for respiratory diagnosis over the
first 2 years of life with dichotomized BPD
as a predictor (c-index, 0.57). Children with
moderate or severe BPD had a 1.82-fold
increase in the odds of a respiratory
diagnosis during the first 2 years of life
(95% CI, 1.22–2.72; P, 0.01). In addition,
a logistic regression was fitted for a
respiratory diagnosis over the first 2 years
of life with the four-category BPD as a
predictor (c-index, 0.63). Children with
severe BPD had a 5.0-fold increase in the
odds of a respiratory diagnosis compared
with those without BPD during the first 2
years of life (95% CI, 2.54–9.68; P, 0.01).
Children with moderate BPD had a 1.64-
fold increase in the odds of a respiratory
diagnosis (95% CI, 0.95–2.83; P = 0.08), and
children with mild BPD had 1.9-fold
increase in the odds of a respiratory
diagnosis compared with those without
BPD (95% CI, 1.15–3.01; P = 0.01). In
comparison with infants with no or mild
BPD, infants with moderate or severe BPD
had significantly more emergency room
visits, hospitalizations, and respiratory
medication use during the first 2 years of
life (Table 7). Importantly, of those infants
diagnosed with moderate or severe BPD,
22% had no clinical evidence of late
Table 5. Subject Characteristics by Respiratory Diagnosis Status
No Respiratory Diagnosis (n = 152) Respiratory Diagnosis (n = 372) P Value
Birth weight, g 970.5 (815 to 1,092.5) 910 (756 to 1,085) 0.14
Birth weight z-score 20.399 (21.04 to 0.24) 20.215 (20.76 to 0.29) 0.06
Birth weight strata, g
500–749 29 (19.1%) 87 (23.4%) 0.28
750–999 57 (37.5%) 140 (37.6%) 0.98
1,000–1,250 66 (43.4%) 145 (39.0%) 0.35
Small for gestational age 52 (34.2%) 89 (23.9%) 0.02
Birth length, cm 35.45 (33 to 37) 35 (32 to 37) 0.03
Birth head circumference, cm 25 (23.5 to 26.5) 24.5 (23 to 26) ,0.01
Gestational age, wk 27 (26 to 29) 27 (25 to 28) ,0.01
Maternal age, yr 29 (25 to 33) 28 (22 to 32) 0.01
Male sex 71 (46.7%) 192 (51.6%) 0.31
Maternal race
Asian 3 (2.0%) 4 (1.1%) 0.42
Black or African American 18 (11.8%) 92 (24.7%) ,0.01
Hawaiian or Pacific Islander 0 (0%) 0 (0%) —
White 130 (85.5%) 273 (73.4%) ,0.01
Other 0 (0%) 1 (0.3%) —
Unknown 1 (0.7%) 2 (0.5%) 0.868
Maternal ethnicity
Hispanic or Latino 30 (19.7%) 69 (18.5%) 0.75
Not Hispanic or Latino 122 (80.3%) 302 (81.2%) 0.81
Multiple gestations 37 (24.3%) 98 (26.3%) 0.63
Antenatal corticosteroids 124 (81.6%) 312 (83.9%) 0.75
Cesarean section delivery 104 (68.4%) 262 (70.4%) 0.65
Intubated in delivery room 85 (55.9%) 239 (64.2%) 0.06
Intubated in NICU 34 (22.4%) 76 (20.4%) 0.87
Surfactant in delivery room 103 (67.8%) 308 (82.8%) ,0.01
PDA medical treatment 62 (40.8%) 149 (40.1%) 0.92
PDA surgical ligation 16 (10.5%) 48 (12.9%) 0.23
IVH grade 3 or 4 6 (3.9%) 15 (4.0%) 0.96
Threshold ROP 4 (2.6%) 37 (9.9%) 0.01
BPD severity
None or mild 105 (69.1%) 205 (55.1%) ,0.01
Moderate or severe 47 (30.9%) 167 (44.9%) ,0.01
Oxygen use at discharge, yes (%) 90 (59.2%) 209 (56.2%) 0.53
Definition of abbreviations: BPD = bronchopulmonary dysplasia; IVH = intraventricular hemorrhage; NICU = neonatal intensive care unit; PDA = patent
ductus arteriosus; ROP = retinopathy of prematurity.
Descriptive statistics [count (percent) or median (interquartile range)] and univariate comparisons for the study demographics, stratified by respiratory
diagnosis over the first 2 years of life.
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respiratory disease after NICU discharge
during early childhood. Of infants without
BPD, 34% were not diagnosed with late
respiratory disease postdischarge. The odds
associated with mild BPD were slightly
higher than the odds for moderate BPD,
although this difference was not significant
(P = 0.62).
Amultiple linear logistic regression was
fitted on respiratory diagnosis using a subset
of predictors from the previous model of
BPD status (Table 8) (c-index, 0.66). A
subset of the predictors included for the
BPD outcome was used for modeling late
respiratory diagnosis owing to the
differences in event rate. Included variables
were selected a priori on the basis of clinical
importance. There was a significant
association between mothers smoking
during pregnancy and children with a
respiratory diagnosis during the first 2 years
of life (P = 0.02) (Table 6). After adjusting
for covariates, we found that children of
mothers who had smoked had increased
odds of a respiratory diagnosis of 2.18 (95%
CI, 1.07–4.44; P = 0.03). Children of white
mothers had a 0.51-fold decrease in the
odds of late respiratory disease compared
with those of other races (95% CI,
0.30–0.87; P = 0.01). Lower gestational age
(OR, 1.15; 95% CI, 1.01–1.30; P = 0.04) was
significantly associated with an increase in
the odds of a late respiratory diagnosis.
Children of mothers who had multiple
gestations had a 1.68-fold increased odds of
late respiratory disease (95% CI, 1.02–2.77;
P = 0.04). Children of mothers who had
preexisting diabetes or gestational diabetes
had a 2.53-fold increase in odds of a late
respiratory diagnosis compared with those
who did not (95% CI, 1.16–5.54; P = 0.02).
Lower maternal age (OR, 1.04; 95% CI,
1.00–1.08; P = 0.03) was significantly
associated with an increase in the odds of a
late respiratory diagnosis. All other
covariates had insignificant ORs. The ORs
from the model are ranked graphically in
Figure 2. Figure 3 displays the common
ORs from the full model predicting BPD
status stacked with the OR from this model.
Finally, children with late respiratory
disease were more frequently exposed to
passive smoking in the household than
those without late respiratory disease
(Table 9). In addition, exposure to
household pets was less common in
children with late respiratory disease.
Discussion
To better understand the contribution of
antenatal factors to the development of BPD
and late respiratory disease during early
childhood, we performed a prospective
longitudinal study of preterm infants that
included extensive data collection of
perinatal, NICU, and postdischarge
information. We report a striking
Table 6. Prenatal Factors by Respiratory Diagnosis Status
Maternal Complications No Late Respiratory Diagnosis Late Respiratory Diagnosis P Value
Preexisting diabetes 3 (2%) 19 (5.1%) 0.11
Gestational diabetes 7 (4.6%) 30 (8.1%) 0.18
Preexisting hypertension 19 (12.5%) 46 (12.4%) 0.89
Prolonged rupture of membranes 26 (17.1%) 72 (19.4%) 0.51
Chorioamnionitis 20 (13.2%) 79 (21.2%) 0.03
Preeclampsia 46 (30.3%) 95 (25.5%) 0.25
Antepartum hemorrhage 14 (9.2%) 47 (12.6%) 0.30
Maternal smoking 11 (7.2%) 55 (14.8%) 0.02
Maternal alcohol use 3 (2.0%) 8 (2.2%) 0.90
Maternal substance abuse 7 (4.6%) 37 (9.9%) 0.05
Descriptive statistics [count (percent)] and univariate comparisons are presented for antenatal events, stratified by respiratory diagnosis over the first 2 years of life.
Table 7. Relationship of Bronchopulmonary Dysplasia Status to Late Respiratory Disease
No or Mild BPD Moderate or Severe BPD P Value
Number of surveys completed 3 (2–4) 3 (2–4) 0.31
Last survey completed, age, mo 24 (18–24) 24 (18–24) 0.94
Number of children with one or more emergency
department visits
167 (48.4%) 142 (58.7%) 0.01
Number of children with one or more emergency
department visits for respiratory reasons
120 (34.8%) 106 (43.8%) 0.10
Number of children with one or more hospitalizations 96 (27.8%) 98 (40.5%) ,0.01
Number of children with one or more hospitalizations
for respiratory reasons
64 (18.6%) 75 (31.0%) ,0.01
Diuretic use 5 (1.4%) 13 (5.4%) 0.01
Bronchodilator use 87 (25.2%) 99 (40.9%) ,0.01
Inhaled steroid use 46 (13.3%) 58 (24.0%) ,0.01
Age when successfully taken off oxygen, d 59 (32–107.5) 180 (98.5–326) ,0.01
Definition of abbreviation: BPD = bronchopulmonary dysplasia.
Data are presented as count (percent) or median (interquartile range).
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association between maternal smoking and
the subsequent diagnosis of moderate and
severe BPD. After adjusting for covariates,
we found that maternal smoking prior to
birth increased the odds of having an infant
with moderate or severe BPD by 2.02-fold.
Maternal smoking was also associated with
prolonged need for mechanical ventilation
and the use of respiratory support during
the NICU admission, as well as with late
respiratory disease during infancy.
Additional risk factors for BPD in this
cohort also included lower gestational age
at birth, lower birth weight z-scores,
white race, and preexisting maternal
hypertension. As shown in Table 3,
decreasing birth weight z-score was an even
better predictor of the development of BPD
than maternal smoking. More infants
with moderate and severe BPD had severe
intraventricular hemorrhage and more
often were treated with surgical ligation of a
patent ductus arteriosus than were those
with no or mild BPD. Overall, these
findings suggest that maternal smoking and
hypertension increase the risk for
developing BPD after preterm birth
and that maternal smoking and
chorioamnionitis are strongly associated
with an increased risk for late respiratory
morbidities during early childhood.
To address ongoing controversies
regarding how well the current National
Institutes of Health definition of BPD at
36 weeks PMA reflects the risk for persistent
respiratory disease during childhood (10,
11), we further examined the relationship
between the diagnosis of moderate or
severe BPD and late respiratory outcomes
during infancy. In this cohort, infants with
BPD had significantly more emergency
room visits, hospitalizations, and
respiratory medication use during the first
2 years of life than those without BPD.
Interestingly, 22% of infants who were
diagnosed with moderate or severe BPD at
36 weeks PMA and 34% without BPD had
no clinical evidence of late respiratory
disease after NICU discharge during early
childhood.
While recognizing the multifactorial
etiologies of BPD, we found that the link
between smoking and BPD risk in our study
cohort to be striking. Previous studies have
shown that maternal smoking is strongly
associated with premature birth, low birth
weight, and abnormal infant lung function
(32, 33). Factors associated with BPD, such
as preeclampsia, preexisting maternal
hypertension, and demographic factors,
Table 8. Model Results of Logistic Regression for Respiratory Diagnosis
Parameter Odds Ratio 95% Confidence Interval P Value
Decreasing birth weight z-score, 1 SD 1.04 0.72–1.50 0.85
Male sex 1.22 0.81–1.83 0.34
Maternal race: white 0.51 0.30–0.87 0.01
Decreasing gestational age, wk 1.15 1.01–1.30 0.04
Maternal smoking status 2.18 1.07–4.44 0.03
Antenatal corticosteroids 1.11 0.62–1.98 0.73
Multiple gestations 1.68 1.02–2.77 0.04
Cesarean section delivery 1.11 0.69–1.80 0.67
Preexisting or gestational diabetes 2.53 1.16–5.54 0.02
Preexisting hypertension 1.15 0.57–2.30 0.70
Prolonged rupture of membranes 0.97 0.55–1.71 0.91
Chorioamnionitis 1.56 0.85–2.83 0.15
Preeclampsia 1.11 0.64–1.92 0.72
Decreasing maternal age, yr 1.04 1.00–1.08 0.03
Risk factors for a respiratory diagnosis over first 2 years of life. Parametric estimates, Wald 95% confidence intervals, and P values derived from the logistic
regression modeling analysis for a respiratory diagnosis over the first 2 years of life.
OR and 95% CI
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Figure 2. Odds ratios (ORs) with 95% confidence intervals (CIs) for model covariates from the logistic
regression analysis modeling respiratory diagnosis over the first 2 years of life.
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were adjusted for in the model to avoid
confounders. Maternal smoking during
pregnancy is a known risk factor for
impaired childhood lung function and
respiratory disease after term birth (34–36).
Pooled analyses of several birth cohort
studies showed that maternal smoking
during pregnancy independently increased
the risk of asthma at 4–6 years of age by 39
to 65% (35). Possible mechanisms include
increased inflammatory cytokine
production, altered placental function, or
direct impact on lung development, which
disrupts lung structure and function (37,
38). In addition, critical interactions
between in utero events with asthma
susceptibility genes suggest a potential
mechanism for gene-by-environment
interactions that may contribute to high
risk for disease (39). We lack quantitative
data to address potential dose–response
relationships between the amount of
smoking and respiratory outcomes in our
population.
Hypertensive disorders of pregnancy,
especially preeclampsia, have previously
been associated with high risk for BPD after
preterm birth. In a small cohort study, the
risk for BPD was dramatically increased in
the presence of preeclampsia, even after
accounting for intrauterine growth
restriction (IUGR) (18). This finding has
been confirmed in some studies (40) but
not in others (41). Our findings extend
previous observations by providing further
evidence for antenatal events that are
strongly associated with respiratory disease
in preterm infants throughout early
childhood. These data are of further interest
because they were obtained from a
prospective longitudinal study that included
strict characterization of BPD definition and
assessment of its severity along with the
inclusion of follow-up assessments
throughout the first 2 years of life to
examine links between BPD severity and
respiratory outcomes during infancy.
Mechanisms through which antenatal
events contribute to high risk for BPD or late
respiratory disease in childhood are at least
partly related to placental abnormalities, as
observed in hypertensive disorders of
pregnancy, preeclampsia, chorioamnionitis,
and other disorders (11, 42, 43). Animal
studies have shown that prenatal insults can
be sufficient to impair lung structure during
infancy, even without adverse postnatal
stimuli (44–46). Researchers in clinical
studies have reported striking associations
between placental histopathology and the
presence of IUGR, as well as high risk for
BPD and BPD with pulmonary
hypertension (42, 43). Preterm human
infants with IUGR have consistently been
shown have a high risk for BPD, providing
strong proof regarding the importance of
fetal events in the pathobiology of BPD (15,
47). In addition to the presence or absence
of BPD at 36 weeks, preterm infants who
were born with IUGR remained at high risk
for abnormal lung function at school age
(48, 49).
Potential limitations of the present study
include that maternal smoking was reported
Odds Ratio and 95% CI
Negative Maternal Age (Years)
Maternal Race: White
Cesarean
Antenatal Corticosteroids
Chorioamnionitis
Prolonged Rupture of Membranes
Pre-existing Hypertension
Multiple Gestations
Gender: Male
Pre-eclampsia
Maternal Smoking Status
Negative Gestational Age (Weeks)
Negative Birthweight Z-Score
5 6 74321
BPD
Respiratory
Figure 3. Comparisons of associations between perinatal factors with bronchopulmonary dysplasia
(BPD) and late respiratory disease models. CI = confidence interval.
Table 9. Environmental Exposures to Passive Smoking and Pets in Subjects with or without Late Respiratory Diagnosis
No Late Respiratory Diagnosis Respiratory Diagnosis P Value
PFT performed 20 (13.2%) 33 (8.9%) 0.14
RSV shots 125 (82.2%) 326 (87.6%) 0.11
Flu shots 130 (85.5%) 324 (87.1%) 0.63
Smoking allowed in child’s home 4 (2.6%) 27 (7.3%) 0.04
One or more people in the home smoke 33 (21.6%) 127 (37.7%) ,0.01
Primary caregivers smoke occasionally or daily 42 (27.6%) 129 (38.6%) 0.02
Families with pets 83 (54.6%) 168 (45.2%) 0.05
Families with dogs 64 (42.1%) 145 (39.0%) 0.51
Families with cats 32 (21.1%) 66 (17.7%) 0.38
Families with other pets 13 (8.6%) 27 (7.3%) 0.61
Definition of abbreviations: PFT = pulmonary function testing; RSV = respiratory syncytial virus.
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by the patient rather than through
biochemical assays for nicotine exposure (50).
We have no evidence that underreporting
rates differed between study groups in our
cohort. In addition, we did not perform
pathologic or histologic assessments of the
placenta to better define chorioamnionitis or
vascular pathology.
In conclusion, we found that maternal
smoking and hypertension increased the
risk for developing BPD after preterm birth
and that maternal smoking is strongly
associated with increased risk for late
respiratory morbidities during early
childhood. Twenty-two percent of infants
diagnosed with BPD and 34% of preterm
infants without BPD had no clinical signs of
late respiratory disease during early
childhood, suggesting that factors beyond
the BPD diagnosis alone modulate
respiratory outcomes in childhood. n
Author disclosures are available with the text
of this article at www.atsjournals.org.
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